about
Nolz1 promotes striatal neurogenesis through the regulation of retinoic acid signalingCystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.Differential neuroprotective effects of 5'-deoxy-5'-methylthioadenosineStriatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicityNovel epigallocatechin-3-gallate (EGCG) derivative as a new therapeutic strategy for reducing neuropathic pain after chronic constriction nerve injury in miceMetabolic profiling for the identification of Huntington biomarkers by on-line solid-phase extraction capillary electrophoresis mass spectrometry combined with advanced data analysis tools.Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system.Helios expression coordinates the development of a subset of striatopallidal medium spiny neuronsAge-dependent maintenance of motor control and corticostriatal innervation by death receptor 3.Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease.Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease.Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction.Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant huntingtin toxicity.Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.Helios transcription factor expression depends on Gsx2 and Dlx1&2 function in developing striatal matrix neurons.A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's diseaseAberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients.BDNF Induces Striatal-Enriched Protein Tyrosine Phosphatase 61 Degradation Through the Proteasome.Striatal-enriched protein tyrosine phosphatase modulates nociception: evidence from genetic deletion and pharmacological inhibitionImbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtinLoss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease.Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms.Chelerythrine promotes Ca2+-dependent calpain activation in neuronal cells in a PKC-independent manner.Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells.Interplay of leukemia inhibitory factor and retinoic acid on neural differentiation of mouse embryonic stem cells.PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease.Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.Dynamics of an F-actin aggresome generated by the actin-stabilizing toxin jasplakinolide.Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism.Glial cell line-derived neurotrophic factor promotes the arborization of cultured striatal neurons through the p42/p44 mitogen-activated protein kinase pathway.Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules.Brain-derived neurotrophic factor prevents changes in Bcl-2 family members and caspase-3 activation induced by excitotoxicity in the striatum.Induction of GABAergic phenotype in a neural stem cell line for transplantation in an excitotoxic model of Huntington's disease.Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.Regulation of c-Ret, GFRalpha1, and GFRalpha2 in the substantia nigra pars compacta in a rat model of Parkinson's disease.Postnatal development of functional dopamine, opioid and tachykinin receptors that regulate acetylcholine release from rat neostriatal slices. Effect of 6-hydroxydopamine lesion.
P50
Q24297178-4D671E5B-0270-47E8-B1C7-B40748CF6E44Q24548047-64018BF4-FABF-4B72-9151-430EA3FEA948Q27317185-854867BC-01DF-4679-842F-DB5C0A036026Q28239309-1AB8A99D-BD85-43A1-ABBE-79EAD86BFBF0Q28546011-3AD81162-531F-4C6F-8A5A-ABDA9BD2E7E8Q31032933-58C7681B-60A5-401A-B898-3CB658DE2DBCQ32050172-51D6F583-2DDC-43DF-83E0-4C4DB764C755Q33588405-E01EDA5D-9FFD-4F13-8027-DBF363EA1ACEQ33894042-F182FAEF-EA7F-4248-9DC3-1FB559A41FABQ34461236-BAEBC3F9-E504-4AA1-9335-EFD4CA3EA97AQ34657624-83353DD0-8E70-4FF8-9D08-75821B281705Q34989074-02F517F8-172A-452B-AAEB-75591F0B1B1AQ35487248-1F56875C-37A2-4A50-A770-0E40AC266F33Q35552239-303FC348-0BAC-4AFB-A032-5DB3DB8FDF83Q35679526-EBEEAF06-E7BB-4F64-8AF2-8F71D6A459A1Q36138530-C8A825E7-972C-4F93-897F-FDA68883743FQ36331582-B04C25BF-A889-47BA-BC47-523B559C57A1Q36410154-8F6F3E12-049F-45A5-AC1B-F918F4E7E541Q36535785-205A68FA-555C-4977-A924-2EF69327227DQ36733262-DA00ADF1-275F-4C67-B6BF-FDB97F0A604EQ36809523-88E814E3-0872-4D64-8DC1-07567FAD07CBQ37153804-A21F853E-B342-45C3-8258-92B2341B0B13Q37644778-0FDD1F65-D342-4D40-A029-261D2B1C1E7CQ38234072-F737E742-A3FD-4079-8707-A64CC5BCC673Q38719051-70373B08-612B-4057-8D6E-ACBDE3878F96Q39767290-3D579154-F854-4717-8EF6-24A43F0BB060Q39789125-5C359A69-2C1C-4ED5-9F87-C42475B878B4Q39800916-A51EDF20-358B-468E-AB65-B3F7F3C8CB7CQ39932912-AC2943F0-70D6-4CD3-AC2D-341C9B30E53CQ39933436-7386E670-38FA-4DB8-AC40-3D726E037D26Q39993908-669DFA9F-264D-4CA0-8B0D-5C34BE7BFA87Q40020558-7A3005A4-652E-4891-92A2-308DEEC059D4Q40199654-892DA790-ADC5-4295-A5D4-87A916E7101BQ40344719-980343B6-ACA7-492A-94EB-85521E54D8F1Q40413623-76DB2219-C2F4-4F67-A546-D346174FE171Q40469094-CF1C17BF-D484-4ACD-88C1-B8EEF1914008Q40506280-44141D0D-8D46-49F0-9B5A-148C0970AF0CQ40519742-697F1650-78AB-41DB-A7E2-C9B8ADBD60A0Q40706788-71F03F20-F12F-4EBD-A584-8EB98C82FA4CQ40728649-184AAF8F-D2C6-4D17-B64C-8E4732202FB3
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Jordi Alberch
@ast
Jordi Alberch
@en
Jordi Alberch
@es
Jordi Alberch
@nl
Jordi Alberch
@sl
type
label
Jordi Alberch
@ast
Jordi Alberch
@en
Jordi Alberch
@es
Jordi Alberch
@nl
Jordi Alberch
@sl
prefLabel
Jordi Alberch
@ast
Jordi Alberch
@en
Jordi Alberch
@es
Jordi Alberch
@nl
Jordi Alberch
@sl
P214
P950
P1053
K-5702-2014
P106
P1153
7003644890
P1580
P21
P213
0000 0000 6089 5468
P214
P31
P3829
P496
0000-0002-8684-2721
P569
1959-01-01T00:00:00Z
P735
P7859
viaf-87614932